InfoMedics' Patient Feedback Survey Results Published in ADA Journal, Diabetes

Survey of type 2 diabetes patients' experiences using long-acting basal insulin

Woburn, Mass. (PRWEB) June 18, 2007 -- InfoMedics, Inc. today announced the publication of data from one of the company's unique, actionable patient feedback survey initiatives in the supplement to the June issue of the American Diabetes Association's journal, Diabetes. The survey assessed differences in self-reported perceptions of insulin detemir, a long-acting basal insulin that provides up to 24 hours of blood sugar control, among patients with type 2 diabetes who were naïve to insulin use vs. those who had used insulin prior to insulin detemir. Titled "Self-Reported Impressions of Insulin Detemir Among Patients with Type 2 Diabetes: Insulin-Naïve vs. Prior Insulin Users", the abstract was written by Donna Kerney, PhD, director of analytics; Diana Paradis, vice president, US Pharma Sales; Laurel Lucrezia, account director, all of InfoMedics; and Stephen Brunton, MD, from Cabarrus Family Medicine Residency, Concord, NC.

"It's exciting to see recognition of InfoMedics' work in Diabetes, a highly respected industry journal," said Paul LeVine, vice president, analytic services of InfoMedics. "This real-world survey is an excellent example of our work in facilitating patient-physician communications. Patient experience data, such as described in this abstract, have proven over time to be instrumental in improving medication compliance, in turn leading to improved treatment outcomes. For patients with chronic diseases such as diabetes, medication compliance can be challenging and to the extent that physicians can understand a patient's impressions of a medication early in the treatment process, they can better manage that patient's treatment in an effort to optimize the outcome."

The abstract describes a real-world survey, in which participating physicians identified patients 18 years or older whom they deemed appropriate for treatment with insulin detemir and provided them with survey information. Patients voluntarily called a toll-free telephone number to enroll and give consent. Participating patients then responded to automated telephone surveys prior to use of insulin detemir and at approximately 30 and 60 days following treatment initiation. Patients answered questions about their perceptions of insulin detemir in terms of weight gain/loss, impact on blood sugar levels, ease of controlling blood sugar levels and overall satisfaction.

While the survey was designed to gather information about all patients' impressions of insulin detemir, secondary analyses were conducted to compare the perceptions of insulin naïve patients vs. those of prior insulin users. Experienced insulin users have an inherent comparison of their current treatment with their prior therapy, while naïve patients may have unrealistic or inaccurate expectations of a new medication. Understanding these potential differences in attitudes at treatment initiation could help physicians to tailor their management of their patients right from the start -- whether it be setting appropriate expectations or encouraging compliance with a new treatment among experienced insulin users.

About InfoMedics, Inc.:

InfoMedics, Inc. is the only pharmaceutical services provider that delivers clear, actionable patient feedback to physicians; this feedback is designed to improve patient-physician communications while providing brand insight to pharmaceutical manufacturers. Patient feedback assists physicians at the point-of-care to optimize treatment outcomes and improve medication compliance. InfoMedics' programs facilitate the communication channel between physicians and patients around the prescribed pharmaceutical brand, enhancing product awareness and accelerating market share growth.

Founded in 1995, InfoMedics' customer base includes 14 of the world's top 15 pharmaceutical companies. The company has delivered over 150 programs across multiple therapeutic areas with industry leading ROI.

For more information, please visit www.infomedics.com

###